Advertisement

New Developments in the Field of Aromatase Inhibitors

  • F. Cavalli
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)

Abstract

Oestrogens play the most important role in maintaining the growth of established breast cancer. Therefore, suppression of circulating plasma levels of oestrogens may induce regression of tumour growth. In premenopausal women the ovaries are the main source of oestrogens, while in postmenopausal women oestrogens are mainly derived from extra-ovarian aromatisation of androgenic precursors such as androstenedione [1].

Keywords

Breast Cancer Metastatic Breast Cancer Aromatase Inhibitor Advanced Breast Cancer Postmenopausal Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Poortman J, Thijssen JHH, Schwarz F: Androgen production and conversion to estrogens in normal postmenopausal women and in selected breast cancer patients. J Clin Endocrinol Metab 1973 37:101–109PubMedCrossRefGoogle Scholar
  2. 2.
    Fishman J: Biochemical mechanism of aromatization. Cancer Res 1982 42 Suppl:3277s-3280sPubMedGoogle Scholar
  3. 3.
    Schindler AE, Ebert A, Friedrich EF: Conversion of androstenedione to estrone by human fat tissue. J Clin Endocrinol Metab 1972 35:627–630PubMedCrossRefGoogle Scholar
  4. 4.
    Nimrod A and Ryan K: Aromatization of androgens by human abdominal and breast fat tissue. J Clin Endocrinol Metab 1975 40:362–372CrossRefGoogle Scholar
  5. 5.
    Schwarzel WC, Kruggel W, Brodie HJ: The development of inhibitors of the enzyme system in human placenta. Endocrinol 1973 92:866–880CrossRefGoogle Scholar
  6. 6.
    Schteingard GE, Cash R, Conn JW: Aminoglutethimide and metastatic adrenal cancer. J Am Med Assoc 1966 198:1007–1010CrossRefGoogle Scholar
  7. 7.
    Gale KE: Treatment of advanced breast cancer with aminoglutethimide: a 14-year experience. Cancer Res 1982 42 Suppl:3389s-3396sPubMedGoogle Scholar
  8. 8.
    Salhanick HA: Basic studies on aminoglutethimide. Cancer Res 1982 42 Suppl:3315s-3321sPubMedGoogle Scholar
  9. 9.
    Abdul-Hajj YJ: Comparative studies of aromatase inhibitors in relation to the significance of estrogen synthesis in human mammary tumors. Cancer Res 1982 42 Suppl:3373s-3377sGoogle Scholar
  10. 10.
    Santen RJ, Wotgul TJ, Lipton A et al: Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann Intern Med 1982 96:94–101PubMedGoogle Scholar
  11. 11.
    Harris AI, Powles TJ, Smith IF: Aminoglutethimide in the treatment of advanced postmenopausal breast cancer. Cancer Res 1982 42 Suppl:3405s-3408sPubMedGoogle Scholar
  12. 12.
    Alexieva-Figusch J, De Jong FH, Lamberts SWJ, Van Gilse HA, Klijn JGM: Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer. Eur J Cancer Clin Oncol 1987 23:1349–1356PubMedCrossRefGoogle Scholar
  13. 13.
    Jakobsen A, Frederiksen PL, Möller KAA et al: Medroxyprogesterone acetate and prednisone in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol 1986 22:1067–1073PubMedCrossRefGoogle Scholar
  14. 14.
    Van Gilse HA: Long-term treatment with corticosteroids of patients with metastatic breast cancer. Cancer Chemother Rep 1962 16:293–298PubMedGoogle Scholar
  15. 15.
    Bisani G, Cocconi G, Ceci G, Franciosi V, Bartolucci R, Gori S, Carpi A, Passalacqua R, Bacchi M: Aminoglutethimide (AG) a bassa dose, con o senza idrocortisone (HC) come prima linea endocrina nel carcinoma avanzato della mammella. Studio prospettico e randomizzato del Goirc. Tumori 1987 73 Suppl:86Google Scholar
  16. 16.
    Mouridsen HT: Endocrine treatment of advanced breast cancer. In: Cavalli F (ed) Endocrine Therapy of Breast Cancer: Concepts and Strategies. ESO Monograph Series, Springer Verlag, Berlin 1986 pp 79–90Google Scholar
  17. 17.
    Smith IF, Harris AI, Morgan M, Gazet JC, McKinna JA: Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res 1982 42 Suppl:3430s-3432sPubMedGoogle Scholar
  18. 18.
    Murray RMI, Pitt P: Aminoglutethimide in tamoxifenresistant patients: The Melbourne experience. Cancer Res 1982 42 Suppl:3437s-3438sPubMedGoogle Scholar
  19. 19.
    Santen RJ: Experience with aminoglutethimide in 147 postmenopausal mammary carcinoma patients. Clinical results and plasma steroid values. In: Paesi FJR (ed) Aminoglutethimide (Orimeten). Mechanism of Action and Clinical Results in Breast Cancer. Ciba-Geigy, Basle 1982 pp 11–34Google Scholar
  20. 20.
    Bonneterre J, Coppens H, Mauriac L, Metz M, Rouesse J, Armand JP, Fargeot P, Mathieu M, Tubiana M, Cappelaere P: Aminoglutethimide in advanced breast cancer: Clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day. Eur J Clin Oncol 1985 21:1153–1158CrossRefGoogle Scholar
  21. 21.
    Stuart-Harris R, Bozek T, Gazet JC, Kurkure A, Dowsett M, McKinna JA, Jeffcoate SL, Carr L, Smith IE: Low dose aminoglutethimide in treatment of advanced breast cancer. Lancet 1984 2:604–607PubMedCrossRefGoogle Scholar
  22. 22.
    Alberto P, Mermillod B, Kaplan E, Goldhirsch A, Obrecht JP, Jungi F, Martz G, Barrelet L, Cavalli F: A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: Low response in patients previously treated with medroxyprogesterone. Eur J Cancer Clin Oncol 1985 21:423–428PubMedCrossRefGoogle Scholar
  23. 23.
    Gelber RD and Goldhirsch A: Methodology of clinical trials. investigating endocrine mechanisms in breast cancer. In: Cavalli F (ed) Endocrine Therapy of Breast Cancer: Concepts and Strategies. ESO Monograph Series, Springer Verlag, Berlin 1986 pp 51–78Google Scholar
  24. 24.
    Zambetti S, Brambilla C, Tancini G, Bonadonna G: Aminoglutethimide in postmenopausal breast cancer refractory to multiple hormonal and cytostatic treatments. Tumori 1987 73:369–373PubMedGoogle Scholar
  25. 25.
    Höffken K, Kempf H, Miller AA, Miller B, Schmidt CG, Faber P, Kley HK: Aminoglutethimide without hydrocortisone in the treatment of post-menopausal patients with advanced breast cancer. Cancer Treat Rep 1986 70:1153–1157PubMedGoogle Scholar
  26. 26.
    Pronzato P, Ardizzoni A, Lionetto R, Conte P, Rosso R: Aminoglutethimide as second-line endocrine treatment in metastatic breast cancer. Tumori 1985 71:297–300PubMedGoogle Scholar
  27. 27.
    Kaye SB, Woods RL, Fox RM, Coates AS, Tattersall HN: Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer. Cancer Res 1982 42 Suppl: 3445–3447Google Scholar
  28. 28.
    Potts GO, Creange JE, Harding HR, Schane HP: Trilostane, an orally active inhibitor of steroid biosynthesis. Steroids 1978 32:257PubMedCrossRefGoogle Scholar
  29. 29.
    Beardwell CG, Hindley AC, Wilkinson PM, Todd IDH, Ribeiro GG, Bu’Lock D: Trilostane in the treatment of advanced breast cancer. Cancer Chemother and Pharmacol 1983 (0:158–160Google Scholar
  30. 30.
    Senn HJ, Varini M: unpublished resultsGoogle Scholar
  31. 31.
    Coombes RC, Dowsett M, Goss PE, Gazett JC, Brodie A: 4-hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet 1984 2:1237–1239PubMedCrossRefGoogle Scholar
  32. 32.
    Hoeffken A, Jonath W, Bossinger K, Kölbel M, Kunz T, Becher R, Callies R: Aromatase inhibition with 4hydroxyandrostenedione (4-OHA) in the treatment of postmenopausal advanced breast cancer. Proceedings 13th Congress of ESMO, 1988, abstract No 180Google Scholar
  33. 33.
    Schieweck K, Bhatnagar AS, Matter A: CGS 16949A, a new non-steroidal aromatase inhibitor: Effects on hormone-dependent and independent tumors in vivo. Cancer Res 1988 48:834–838PubMedGoogle Scholar
  34. 34.
    Steele RE, Mellor L, Sawyer WK, Wasvary JM, Browne LJ: In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A. Steroids 1988 (in press)Google Scholar
  35. 35.
    Beretta K, Willems Y, Nadjafi C, Sessa C, Cavalli F: Phase I-II study in postmenopausal patients with advanced breast cancer of CGS 16949A: a new highly potent and selective aromatase inhibitor. Proceedings 13th Congress of ESMO, 1988, abstract No 181Google Scholar
  36. 36.
    Lipton A, Harvey HA, Demers LM, Hanagan J, Mulagha M, Sanders S, Fritzsimmons S, Santen RJ: A phase I trial of CGS 16949A - A new aromatase inhibitor. Proceedings 13th Congress of ESMO, 1988, abstract No 125Google Scholar
  37. 37.
    Stein RC, Davenport J, Hedley A, Coombes RC: Preliminary study of CGS 16949A in advanced postmenopausal breast cancer. Proceedings 13th Congress of ESMO, 1988, abstract No 182Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • F. Cavalli
    • 1
  1. 1.Division of OncologyOspedale San GiovanniBellinzonaSwitzerland

Personalised recommendations